MONDAY

• Overview: Global BioBusiness
  J. Zuercher, Ernst & Young SA
  

• Assessing Technology & Market
  Opportunities
  S. Mehta, Rensselaer Polytechnic Institute
  

• BioProject: Participants’ Projects
  

• The Humabs Case
  A. Lanzavecchia, IRB and A. Harfstrand, HUMABS BioMed
  

• Start-up an Opportunity
  S. Mehta, Rensselaer Polytechnic Institute
  

• Business Plan
  L. Leoni, AGIRE
  

• Start-up Phase & Opportunity
  Recognition: the ESBATech Case
  A. Barberis, TeLoRmedix SA
  

• BioProject: Participants’ Projects

TUESDAY

• Evolution of Business Models
  S. Mehta, Rensselaer Polytechnic Institute
  

• Preclinical and Clinical Drug Development
  R. Fariello, Neurotune SA
  

• BioProject: Participants’ Projects
  

• Company Presentations
  P. Botti, ArisGen and A. Ghasparian, Virometix
  

• From Scientist to CEO
  C. Zahnd, Molecular Partners
  

• BioProject: Participants’ Projects

WEDNESDAY

• Intellectual Property Rights
  P. Felder, Schmauder & Partner AG
  

• BioProject: Participants’ Projects
  

• Registration in Europe
  U. Granzer, Granzer Regulatory Consulting & Services
  

• BioProject: Participants’ Projects
  

• Principles of Project Valuation
  E. Nowak, USI, IFIN
  

• Valuation & Negotiation in Life Sciences
  P. Frei, Venture Valuation
  

• Evening Event

THURSDAY

• Venture Capital for Early-Stage
  Opportunities
  R. Fleck, Index Ventures
  

• Fundamentals of Sales & Marketing
  R. Cervini, Helsinn Advanced Synthesis SA
  

• BioProject: Participants’ Projects
  

• Sales Pitch to Investors,
  S. Therianos, Diagnoplex
  

• Stages of the Investment Process
  J.-P. Tripet, Aravis SA
  

• BioProject: Participants’ Projects

 

FRIDAY

• Exit Strategies
  M. Alder, Former VP Micromet
  
• Selection Process for a successful Investment: a VC Point of View
  E. Braglia, Onelife Advisors SA
  
• BioProject: Participants’ Projects
  
• Support Programs and Business Angels
  in Switzerland
  J.-P. Vuilleumier, CTI Invest
  
• M&A: Expansion Strategy for Pharma
  Companies and Exit Strategy for Biotech
  Enterprises
  R. Braglia, Helsinn Group
  
• Participants’ Presentations
  
• Helsinn Award for the best BioProject
  
• Feedback and Closing Remarks